Aims: Androgen deficiency has been implicated in urological complications of postmenopausal women. This study examined the effects of testosterone replacements on the lower urinary tract dysfunction in 4-month old ovariectomized (OVX) rats. Main methods: Sprague-Dawley female rats were OVX bilaterally. Three months later, rats received single intramuscular injections of testosterone undecanoate. Cystometric study, and bladder and urethra smooth muscle reactivities were evaluated. Key findings: Ovariectomy reduced by 65% (p b 0.05) the serum testosterone levels. Testosterone replacement at 5 mg/kg restored serum hormone levels to baseline, whereas 10 mg/kg produced 14-fold higher testosterone levels. OVX rats exhibited significant increases of body weight, perigonadal fat and blood pressure, and reduced uterus weight, but none of these parameters were changed by testosterone replacements. OVX rats exhibited micturition dysfunction characterized by increases of basal pressure, threshold pressure, voiding frequency and post-voiding pressure. In addition, the bladder contractions induced by electrical-field stimulation (EFS) and carbachol were significantly reduced, whereas angiotensin II-induced urethral contractions were significantly increased in OVX rats. Testosterone replacement at 10 mg/kg (but not at 5 mg/kg) dose fully normalized the in vivo micturition dysfunction, as well as the in vitro bladder and urethral alterations. Testosterone (10 mg/kg) also significantly potentiated the bladder relaxations induced by the β 3 -adrenoceptor agonist mirabegron. The protective effects of testosterone were not modified by concomitant treatment with the aromatase inhibitor letrozole (2.5 mg/kg, 4 weeks). Significance: The improvement of micturition dysfunction by testosterone replacement suggests that androgen therapy might be of therapeutic benefit for urological complications associated with post-menopause.
Introduction
Overactive bladder syndrome (OAB) is a complex and multifactorial entity with a significant worldwide prevalence and economic impact, particularly in ageing population [1] . Overactive bladder consists of urgency with or without urgency urinary incontinence, usually accompanied by daytime frequency and nocturia in the absence of urinary tract infections or other obvious pathologies [2] . Postmenopausal women experience a number of age-related changes, including urological complications such as OAB and recurrent urinary tract infections [3] [4] [5] [6] . Overactive bladder has a great negative impact in the quality life of postmenopausal women because it affects daily activities and social interactions [7] , despite this is frequently underreported and underdiagnosed.
Treatment of OAB includes lifestyle advice, behavioral modifications, bladder retraining and pelvic floor muscle training, usually in combination with antimuscarinic agents. The β 3 -adrenoceptor agonist mirabegron has also successfully emerged as a new class of drug able to improve OAB symptoms by its capacity to relax bladder tissue [8] .
The rat ovariectomy model has been widely used to mimic menopause, provided it decreases sex steroids hormone, increases body weight and blood pressure, and promotes morphometrical changes in the reproductive organs [9] [10] [11] . Ovariectomized rats exhibit micturition alterations characterized by increases of voiding frequency, as well as by in vitro bladder and urethra smooth muscle alterations [12] [13] [14] . Ovariectomy is reported to produce a disruption of the coordination between urethra and detrusor muscle, which that presumably accounts for the poor bladder emptying efficiency [15] . However, studies involving sex steroids hormone deficiency and bladder dysfunction are still scarce.
Testosterone is produced by the adrenal cortex and ovaries, and the summation of both sources account for approximately 50% of the Life Sciences 179 (2017) [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] circulating hormones in women during the reproductive years, decreasing progressively with age [16] . Testosterone replacement therapy in postmenopausal women has been employed for the lack of sexual desire, although it may have favorable effects on bones, muscle mass, and cognitive function [17] [18] [19] . It has been suggested that androgen deficiency may account for the lower urinary tract disorders in women [20, 21] . A study carried out in ovariectomized rats also demonstrated that testosterone increases the contractile response of bladder to both neurogenic stimulation and muscarinic agonist activation with carbachol [14] . Literature on menopause often explores the impact of estrogen loss on various physiopathological effects [22] [23] [24] , whereas the effects of androgen deprivation and its replacement in bladder dysfunction require more investigation in experimental models. The supplementation with androgens in postmenopausal women has been based on recuperating its normal physiological levels, which is employed by using doses lower than those administered to men; however, this is still rather imprecise [10] . Therefore, in the present study we used the model of rat ovariectomy to evaluate the effects of testosterone replacements at different doses on the in vivo micturition dysfunction, as well as on the isolated bladder and urethra smooth muscle alterations. Taken into consideration that testosterone may be converted by aromatase (CYP19) to estrogen, and that this hormone restores bladder dysfunction on ovariectomized (OVX) rats [13] , we further explored the effects of the aromatase (CYP19) inhibitor letrozole in combination with testosterone on the lower urinary tract dysfunction.
Materials and methods

Animals
All animal procedures and experimental protocols were according to the Ethical Principles in Animal Research adopted by the Brazilian College for Animal Experimentation and approved by the Institutional Committee for Ethics in Animal Research of State University of Campinas (Protocol No 3500-1). Two-month old female Sprague-Dawley rats weighing 250 to 280 g were housed at constant room temperature with 12 h light and dark cycles. Food and water were available ad libitum.
Bilateral ovariectomy
The animals were anesthetized with Ketamine/Xylasine (60:6 mg/kg, intraperitoneal). Bilateral incisions were made, the vascular supply ligated and the ovaries removed. The muscle layer was sutured, and the incisions closed with a cotton suture. Sham-operated rats were subjected to surgery and the ovaries manipulated, but left intact.
Testosterone replacement in OVX rats
Three months after the OVX, rats were intramuscularly injected with testosterone undecanoate (Nebido®; Bayer Pharma AG) at single doses varying from 1.0 to 100 mg/kg, or the corresponding vehicle (Castor oil). At 1-month after testosterone injection (or 4-months after OVX), rats were killed under anesthesia. The body weight, perigonadal fat mass, and uterus, bladder and urethra weights were determined. These experimental protocols consisted of eight groups, namely: a) Sham + vehicle, b) OVX + vehicle, c) OVX + 1.0 mg/kg testosterone, d) OVX + 2.5 mg/kg testosterone, e) OVX + 5.0 mg/kg testosterone, f) OVX + 7.5 mg/kg testosterone, g) OVX + 10.0 mg/kg testosterone, and h) OVX + 100.0 mg/kg. The doses of testosterone were employed according to previous studies [14, 25] . The protocol design is illustrated below.
Effects of the aromatase (CYP19) inhibition in OVX rats
An independent group of OVX rats were treated with testosterone alone and in combination with the aromatase inhibitor letrozole. Briefly, three months after the OVX, rats received a single injection of testosterone (10 mg/kg, i.m.) in combination or not with letrozole (2.5 mg/kg, given by gavage during the last four weeks of ovariectomy), according to a previous study [26] . The vehicle used for letrozole was Transcutol/ Cremophor®/Water (1:2:7, vol/vol; Sigma Chem Co). These experimental protocols consisted of four groups, namely: a) Sham + vehicle, b) OVX + vehicle, c) OVX + testosterone and d) OVX + testosterone + letrozole.
Cystometric evaluation
Rats were anesthetized by intraperitoneal injection of urethane (1.8 g/kg). A 1-cm abdominal was made along midline of abdomen of the animals to expose the bladder and a butterfly cannula (23G) was inserted in the bladder dome. The cannula was connected to a 3-way tap, of which 1 port was connected to the infusion pump through a PE-50 catheter and the other to the pressure transducer. Before starting cystometry, the bladder was emptied, an equilibrium period was allowed before saline infusion and regarding cystometric parameters. Continuous cystometry was performed by saline infusion in the bladder at 4 mL/h for 45 min. Bladder pressure were recorded with an acquisition system with the specific Software PowerLab 4/35 (ADInstruments Inc., New South Wales, Australia). The following parameters were assessed: basal pressure, capacity (volume needed to induce first micturition), threshold pressure (intravesical pressure immediately before micturition), compliance (ratio between bladder capacity to threshold pressure); voiding pressure (pressure reached during micturition), voiding frequency, non-voiding contractions frequency (NVCs, spontaneous bladder contractions higher than 4 mm Hg from the baseline pressure that did not result in a void) and post-micturition pressure (intravesical pressure immediately after micturition) [27] . The animals used in cystometry studies were not reused in other experiments. One cystometrogram was obtained for each rat.
Functional assays in isolated bladder
Rats were stunned by inhalation of CO 2 , euthanized by decapitation and exsanguinated. The bladder was isolated and placed in KrebsHenseleit solution with the following composition (mM): 117 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25 NaHCO 3 , and 11 glucose, pH 7.4, at 37°C and bubbled with a gas mixture of 95% O 2 and 5% CO 2 . The dome of bladder with intact urothelium (detrusor muscle and mucosa) was separated, cut in two longitudinal strips and placed in 4-mL organ baths [13] . One part of strip was fixed and the other was connected in the force transducer and coupled to data acquisition system PowerLab 4/30. The preparation was maintained in Krebs solution and aerated continuously with O 2 /CO 2 mixture (95:5%) at 37°C. The bladder preparation was stabilized for 60 min, replacing Krebs solution every 15 min, and tension was adjusted to 20 mN. The contractile response to depolarizing agent KCl (80 mM) was evaluated. Cumulative concentration-response curves to the full muscarinic agonist carbachol (1 nM-100 μM) were evaluated using one-half logarithm unit. Relaxing responses to cumulative concentrations of the selective β 3 -adrenoceptor agonist mirabegron (1 nM-1 mM) were evaluated in pre-contracted tissues, using one-half logarithm unit. Nonlinear regression analysis to determine the pEC 50 was carried out using GraphPad Prism Software with the constraint that F = 0. All concentration-response data were evaluated for a fit to a logistics function in the form: E = E max / ([1 + (10c / 10x) n] + F), where E is the maximum response produced by agonist; c is the logarithm of the EC 50 , the concentration of drug that produces a halfmaximal response; x is the logarithm of the concentration of the drug; the exponential term, n, is a curve-fitting parameter that defines the slope of the concentration-response line, and F is the response observed in the absence of added drug. Values of maximal contractile responses (E max ) were represented by mN/mg of tissue and relaxing responses were calculated as percentages of the maximal changes from the steady-state contraction produced by carbachol in each tissue.
Functional assays in isolated urethra
The urethra was removed, cut in one ring and mounted in 5-mL organ baths containing Krebs-Henseleit solution (same composition as above for bladder), aerated continuously with O 2 /CO 2 mixture (95:5%) at 37°C. Changes in isometric force were recorded using force transducer and coupled to data acquisition system PowerLab 8/30. Tissues were allowed to rest for 60 min, replacing Krebs solution every 15 min and tension was adjusted to 2 mN. The contractile response to depolarizing agent KCl (80 mM) was measured. Cumulative concentration-response curves to angiotensin II (100 pM-10 μM) were evaluated using one-half logarithm units. Data were normalized by the wet weight of the respective urethral ring, and values of E max were represented by mN/mg of tissue.
Bladder contractions induced by electrical-field stimulation
Electrical field stimulation (EFS) was applied to bladder strips placed between two platinum ring electrodes connected to a S88 stimulator (Grass Technologies, Rodhe Island, USA). EFS was conducted at 80 V, 1 ms pulse width and trains of stimuli lasting 10 s at varying frequencies (1-32-Hz). Data were normalized by the wet weight of bladder strips, and the values of E max were represented by mN/mg of tissue.
Measurement of serum levels of testosterone
Arterial blood was collected for measurement of serum total testosterone levels, using a chemiluminescence technique (Vetpat Laboratory, Campinas, Sao Paulo, Brazil).
Systolic blood pressure measurements
Systolic blood pressure was evaluated in the last week of treatments in all groups, using a tail-cuff method. The measurements were recorded in non-invasive blood pressure controller coupled with an acquisition system with the specific Software PowerLab 4/35 (ADInstruments Inc., New South Wales, Australia). The experiments were carried out in conscious animals in a quiet room. Blood pressure was represented as the means of at least three alternate day recordings.
Statistical analysis
Data are presented as mean ± standard error of mean (SEM). Statistical significance was calculated by one-way ANOVA followed by Bonferroni's multiple comparison test (GraphPad Software, California-USA). p value b 0.05 were considered significant.
Results
Serum testosterone levels
Bilateral OVX reduced by 65% (p b 0.05) the serum testosterone levels compared with Sham group (Fig. 1) . Testosterone replacement at 1.0 to 100 mg/kg was then performed in OVX rats, and serum levels of this hormone were measured at four weeks thereafter. In OVX rats, testosterone replacement at 2.5 at 7.5 mg/kg restored the hormone to the levels of Sham group, whereas doses of 10 and 100 mg/kg promoted 14-and 27-fold higher levels compared with untreated OVX rats ( Fig. 1; p b 0.05) .
Body, uterus, bladder and urethra weights
Ovariectomized rats exhibited significant increases in the body weight compared with Sham group (p b 0.05), which remained unchanged by testosterone replacement in all doses used ( Fig. 2A) . The uterus weight in OVX rats markedly reduced compared with Sham group (p b 0.05), and this reduction was unaffected by testosterone replacements, except at the dose of 100 mg/kg where a slight (despite significant) reversion on uterus weight was observed (p b 0.05; Fig. 2B ). The bladder and urethra weights remained unchanged by OVX or testosterone replacements in all doses as compared with Sham group (Fig. 2C,D) .
For the further studies below-described, we routinely employed testosterone at 5.0 and 10 mg/kg, which restores the serum concentration to physiological and supraphysiological levels, respectively.
Perigonadal fat mass and blood pressure
A marked increase in the perigonadal fat mass by about of 60% was observed in OVX compared with Sham group (p b 0.05), which remained unaffected by testosterone replacement at either physiological or supraphysiological doses ( Table 1) . The arterial blood pressure in OVX group also significantly increased when compared with Sham (p b 0.05), which was also unaffected by testosterone in both doses (Table 1) .
Cystometric study in anesthetized rats
Compared with Sham rats, the micturition patterns in OVX group were irregular (Fig. 3A) and characterized by significant increases (p b 0.05) of basal pressure, threshold pressure, voiding frequency and post-voiding pressure ( Fig. 3B-E) . The bladder capacity, frequency of non-voiding contractions (NVCs), voiding pressure and compliance in OVX did not significantly differ from Sham rats ( Table 2) . In OVX rats, testosterone replacement at supraphysiological (T10) dose fully prevented the increases in basal pressure, voiding frequency and postvoiding pressure (Fig. 3B,D,E) , whereas the threshold pressure remained elevated (Fig. 3C) . The other cystometric parameters were not significantly affected by this dose of testosterone (Table 2) . Testosterone given at the physiological dose (T5) had no effect in any of the cystometric alterations (Fig. 3, Table 2 ).
Contractile responses to carbachol and electrical-field stimulation (EFS) in isolated bladder
Cumulative addition of the full muscarinic agonist carbachol (1 nM to 100 μM) in isolated bladders produced concentration-dependent contractions in all groups (Fig. 4A) . However, the maximal contractions (Emax) in OVX group were significantly reduced compared with Sham group (Fig. 4B; p b 0.05) . Testosterone replacement at physiological levels did not modify the reduced bladder contractions in OVX group. At supraphysiological levels; however, testosterone fully restored the bladder contractions to the levels of Sham group (Fig. 4A,B) . No statistically differences for the potency (pEC 50 ) values for carbachol between groups were observed ( Table 3 ). The contractile bladder responses to KCl (80 mM) did not significantly modify between groups (0.96 ± 0.12, 1.06 ± 0.07, 1.10 ± 0.27 and 1.24 ± 0.21 mN/mg for Sham, OVX + vehicle, OVX + 5 mg/kg of testosterone and OVX + 10 mg/kg of testosterone, respectively).
Electrical-field stimulation (1-32 Hz) of the bladder tissues caused frequency-dependent neurogenic bladder contractions in all groups. In OVX group, however, the EFS-induced contractions were lower at all frequencies tested (p b 0.05; Fig. 5A ). Testosterone replacement at physiological levels did not modify the reduced EFS-induced bladder contractions in OVX groups. However, at the supraphysiological level, testosterone fully restored the bladder contractions to the levels of Sham group in all frequencies tested (Fig. 5A,B) .
Relaxing responses to the β3-adrenoceptor agonist mirabegron in isolated bladder
The bladder relaxations were evaluated by cumulative addition of mirabegron in carbachol (1 μM)-precontracted tissues. The levels of pre-contractions did not significantly differ between groups (0.48 ± 0.08, 0.40 ± 0.08, 0.35 ± 0.04 and 0.46 ± 0.09 mN/mg for Sham, OVX + vehicle, OVX + 5 mg/kg and OVX + 10 mg/kg testosterone, respectively).
Mirabegron (1 nM-1 mM) produced concentration-dependent relaxations in all groups with similar maximal responses in Sham and OVX groups (87.0 ± 7.5 and 84.3 ± 6.4%, respectively; Fig. 6A ). Testosterone replacement at supraphysiological (but not at physiological) level significantly potentiated (p b 0.05) the mirabegron-induced bladder relaxations in OVX compared with the other groups (Fig. 6A,B) . No statistically differences for the potency (pEC 50 ) of mirabegron were observed between groups (Table 3) .
Contractile responses to angiotensin II in urethra
Cumulative addition of angiotensin II (100 pM-10 μM) produced concentration-dependent urethral contractions, which were markedly greater in OVX compared with Sham group (Fig. 7A; p b 0.05) . Testosterone replacement at supraphysiological (but not at physiological) level restored the urethral contractions to the levels of Sham group (Fig. 7A,B) . No statistical differences in the potency (pEC 50 ) for angiotensin II between groups were observed ( Table 3) .
The contractile responses to KCl (80 mM) were higher in OVX rats treated with testosterone at 10 mg/kg compared with the other groups (p b 0.05) (0.23 ± 0.01, 0.15 ± 0.02, 0.20 ± 0.07 and 0.39 ± 0.01 mN/mg for Sham, OVX + vehicle, OVX + 5 mg/kg of testosterone and OVX + 10 mg/kg of testosterone, respectively). 
Effect of testosterone in association with letrozole
We next designed experiments to investigate if the beneficial effects by testosterone were secondary to its conversion to estrogen by aromatase (CYP19) [28] . To achieve this, OVX rats received testosterone (10 mg/kg, i.m.) in combination or not with the aromatase inhibitor letrozole (2.5 mg/kg, gavage, four weeks), after which cystometric and in vitro studies were carried out.
In the urodynamic study, the attenuation by testosterone of the increases of basal pressure, voiding frequency and post-voiding pressure in OVX rats remained unchanged by concomitant treatment with letrozole (Fig. 8A,B,D,E) . Either testosterone alone or in combination with letrozole failed to affect the increased threshold pressure in OVX rats (Fig. 8C) . The other cystometric parameters (bladder capacity, frequency of NVCs, voiding pressure and compliance) were not changed between groups (not shown).
Likewise, in the isolated bladder and urethra, the reversal by testosterone of the decreased bladder contraction (Fig. 9A,B) and the increased urethral contraction (Fig. 9C,D) in OVX rats remained unchanged by concomitant treatment with letrozole.
Discussion
The lower urinary tract dysfunction in postmenopausal women is clinically relevant [29] . Testosterone replacement therapy has been shown to alleviate sexual, cognitive and cardiovascular problems during post-menopause [17, 30] , but few studies have examined the effects of testosterone replacement on the bladder and urethral smooth muscle dysfunctions. The main findings of the present study are a) 4-month old OVX rats clearly show in vivo and in vitro bladder dysfunction, proving a suitable experimental model for exploring the lower urinary function in menopause; b) testosterone given at supraphysiological levels normalizes the in vivo micturition dysfunction and in vitro bladder and urethral smooth muscle dysfunction, whereas at physiological levels this hormone has no significant effect; and c) the beneficial effect of supraphysiological dose of testosterone on the lower urinary tract dysfunction is not altered by concomitant treatment with the aromatase inhibitor letrozole.
Removal of the ovaries by bilateral ovariectomy in rats led to a marked reduction of total testosterone levels in serum, a model that allows an exogenous supply of this hormone at varying concentrations in order to evaluate the effects of its replacement. In the present study, when testosterone was employed in the range of doses of 2.5 to 7.5 mg/kg, the serum concentrations of this hormone achieved the baseline of the Sham group, whereas doses over 10 mg/kg led to serum concentrations markedly greater than baseline. Therefore, for most of our assays, we employed 5 and 10 mg/kg of testosterone to mimic physiological and supraphysiological levels, respectively.
The bladder and urethra work as a functional unit to maintain the urinary continence. The bladder smooth muscle is densely innervated by parasympathetic fibers that upon stimulation release acetylcholine that promotes bladder emptying through activation of muscarinic receptors in detrusor [31] . Muscarinic M 3 receptors are functionally more important for the urinary bladder contractions, even though its density is lower as compared with the population of muscarinic M 2 receptors. Beside the parasympathetic system, the bladder and urethra smooth muscles receive a rich sympathetic innervation. In bladder, noradrenaline released from sympathetic nerve fibers activates β 2 and/or β 3 -adrenoceptors in bladder generating tissue relaxations, contributing to the filling phase during the micturition cycle [32] . The lower urinary tract innervation and its contractile function are reported to be disrupted during periods of marked changes in female hormone levels, such as menopause [31] . Accordingly, OVX rats display significant decreases in voided volume and increases in voiding frequency, possibly as a result of a disturbance between the coordination of detrusor smooth muscle and external urethral sphincter [15] . In the present study, the urodynamic studies in the 4-month old OVX rats showed micturition dysfunctions characterized by increases of voiding frequency, basal pressure and post-micturition pressure, evidencing an overactive bladder with a poor bladder emptying profile. We next moved to examine the bladder and urethral smooth muscle contractility in vitro. We found that the in vitro bladder contractions induced by electrical-field stimulation (EFS) in OVX rats were significantly reduced compared with Sham group, which is in line with a previous study showing that ovariectomy itself decreases the contractile responses of the detrusor muscle to electrical-nerve stimulation [33] . Likewise, in OVX rats, the direct activation of the muscarinic receptors with carbachol resulted in reduced bladder contractions. The testosterone replacement at supraphysiological dose fully normalized the cystometric alterations (frequency, basal pressure, threshold pressure and postvoiding pressure), as well as the reduced EFS-and carbachol-induced bladder contractions in OVX rats. Previous studies examined the muscarinic receptor density in bladders of OVX rats, but found no significant changes in the muscarinic M 3 receptor population compared with Sham group [34, 35] . We therefore suggest that improvement by testosterone of bladder function may be due to changes in affinity and/or efficacy of the muscarinic receptors, which is reinforced by the findings that bladder contractions in depolarizing conditions (KCl) remain unaffected by ovariectomy in the absence or the presence of testosterone replacement. Mirabegron is a new described selective β 3 -adrenoceptor agonist recommended for treatment of overactive bladder, including women [36] . In our study, mirabegron produced concentration-response bladder relaxations that were unaffected by ovariectomy. Interestingly, however, testosterone at supraphysiological dose largely potentiated the mirabegron-induced bladder relaxations in OVX rats. Previous studies have reported a relationship between androgens and β-adrenoceptor [37] . For instance, castration in rats decreased the β 1 -adrenoceptor mRNA levels in cardiac tissues, which was markedly elevated by testosterone treatment [38] . The androgen androlone decanoate also increased the expression of cardiac β 2 -adrenoceptors in rats [39] . In our study, whether the potentiation of mirabegron-induced bladder relaxations by testosterone in OVX rats is due to increases of β 2 and/or β 3 -adrenoceptor densities in bladder requires additional studies.
Angiotensin II plays a significant role not only in the cardiovascular system and brain, but also in the lower urinary tract system [40] . The circulating levels of angiotensin II are increased in experimental model of menopause, possibly as a consequence of the sex steroids deficiency [41, 42] . Angiotensin II produces concentration-dependent contractions in rat isolated urethra smooth muscle that is significantly enhanced by OVX [13] . We found that supraphysiological levels of testosterone normalized the angiotensin II-mediated urethral hypercontractility in OVX rats. Interestingly, in bladders of castrated rats, there has been reported an increased expression of angiotensin AT 2 receptor and its MAP-kinase signaling pathway, which are significantly attenuated by testosterone administration [43] . Since angiotensin II-mediated urethral contractions take place by AT 1 receptor activation [44] , it is possible that such receptor expression is androgen-dependent in the urethral tissue, being down-regulated by testosterone replacement.
In OVX rat, the source of estrogen is given by the extra-gonadal aromatization of testosterone by aromatase (CYP19) in different sites, including the adipose tissue [45] . Given that the effects produced by testosterone replacement would be secondary to estrogen production via androgen aromatization by aromatase [46] , we tested the hypothesis that beneficial effects of supraphysiological dose of testosterone on lower urinary tract dysfunction of OVX rats would be a consequence of increased estrogen synthesis, thus triggering its downstream signaling via estrogen receptors (ERα/ERβ) [14] . OVX rats were then treated with testosterone concomitantly or not with the aromatase inhibitor letrozole. Our data showed that the protective effects of testosterone on the in vivo micturition dysfunction and in vitro bladder and urethral contractions remain unaltered by letrozole treatment, excluding the contribution of estrogen on beneficial effects of the lower urinary tract in this experimental model. It is more likely that testosterone directly counterbalance the effects of ovariectomy by activating different signaling pathways at intracellular levels in the lower urinary tract smooth muscle (bladder and urethra). Accordingly, androgen receptors have been identified in bladder urothelium and smooth muscle, striated muscle of the urethra, and neurons in the autonomic pelvic [47, 48] . Androgen receptors (AR) are distributed in the vascular smooth muscles and endothelial cells, the activation of which induces the release of NO and hence vasorelaxation [46, 49] . However, endothelial denudation attenuates but does not fully abolish testosterone-induced vasorelaxation, suggesting that other mechanisms are implicated in this response [50] . Recently, testosterone and other androgens were shown to produce direct peripheral vasodilation via neuronal NO synthase activation, independently of AR activation [50] . Taken together, the role of testosterone and its signaling pathway in each physiological system is complex depending on type of tissue and its function, as well as the hormonal status of the animal and/or subjects. Additionally, in the lower urinary tract smooth muscle, NO acts as an inhibitory transmitter to regulate bladder and urethral smooth muscle tone, neurotransmission and blood flow [51] . Evidence suggests that impairment of NO signaling pathway accounts for overactive bladder [52] . Bladder ischemia and the accompanying enhanced oxidative stress are reported to cause storage symptoms [53] . Therefore, in the OVX model, the loss of steroidal hormones and consequently the removal of NO at the level of the iliac artery may lead to local ischemia, triggering the voiding alterations. In this context, testosterone replacement at supraphysiological would restore the diminished local blood flow as well as directly counteract bladder dysfunction in this experimental model. Despite androgen receptors have been found bladder and urethra [47, 48] , no study yet attempted to investigate the coupling of androgen to NO release.
There is evidence that depletion of sex steroid hormones during menopause contributes to weight gain that increases the risk for obesity, metabolic syndrome, type-2 diabetes and hypertension [42] . Overweight, obesity and metabolic syndrome in women, in turn, have been significantly associated with overactive bladder [54] . Low levels of estrogen during animal ovariectomy lead to endothelial dysfunction and decreased NO release, which is associated with increased oxidative stress and arterial hypertension [11] . In our study, OVX rats displayed increases of body measures (body weight and perigonadal fat) and arterial blood pressure, which is prevented by replacement therapy with 17β-Estradiol [13] . However, the increases of body measures and arterial pressure were unaffected by testosterone replacements, confirming the local effect of testosterone on lower urinary tract, and excluding the possibility that estrogen synthesis is taking place by extra-gonadal aromatization by aromatase (CYP19) in OVX rats given that letrozole did not change the beneficial effects of testosterone replacement.
In conclusion, this study shows that 4-month ovariectomy in rats produces micturition dysfunction characterized by increases of frequency, basal pressure, threshold pressure and post-voiding pressure, together with reduced bladder contractions to muscarinic activation and enhanced angiotensin II-induced urethral contractions. Testosterone given at a supraphysiological dose in OVX rats normalized the in vivo and in vitro lower urinary tract dysfunctions. Therefore, therapy with androgens might be of therapeutic benefit for the post-menopause-associated urological complications.
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